European Journal of Heart Failure

FEBRUARY 5, 2025

Methods and results TRED-HF was a randomized trial investigating heart failure therapy withdrawal in patients with recovered DCM over 6months. Participants were recommended to restart therapy post-trial and were followed until May 2023. Those randomized to continue therapy subsequently withdrew treatment between 6 and 12months.

Heart Failure 67

Heart Failure Cardiomyopathy Atrial Fibrillation Arrhythmia 67

European Journal of Heart Failure

OCTOBER 31, 2023

This 2023 Cochrane review of 60 randomized trials in 8728 heart failure patients, confirms the benefits of participation in exercise-based cardiac rehabilitation (ExCR), including reduced risk of hospitalization and a clinically meaningful improvement in health-related quality of life. 1.01, MLWHF: −9.59, 95% CI −17.48

Cardiac Rehabilitation 40

Cardiac Rehabilitation Heart Failure Exercise Quality of Life 40

Cardiometabolic Health Congress

NOVEMBER 16, 2023

2-5, 2023, to gain perspective on the latest advances in the management of glomerular disease. Kidney Week 2023 not only served as a platform for the latest news and updates in the field but also marked the final meeting of the year for practitioners in the specialty of nephrology.

Kidney Disease 52

Kidney Disease Blood Pressure Diabetes Hospital 52

Journal of Cardiovascular Pharmacology

DECEMBER 20, 2023

Background: Midodrine is occasionally used off-label to treat hypotension associated with advanced heart failure. Objectives: We sought to evaluate the effect of midodrine upon the GDMT prescription pattern and clinical outcomes of patients with decompensated systolic heart failure. All rights reserved.

Heart Failure 52

Heart Failure Hospital Outcomes Article 52

Cardiology Update

JANUARY 2, 2024

Important Deadlines: Early registration fee: January 9, 2023. Late registration fee: February 8, 2023. Important Deadlines: Abstract and late-breaking clinical trial submission is closed (Deadline: December 7 and October 17, 2023) Fees: Visit the ACC 2024 website for registration options. Hashtag: #ACVC2024 2. Hashtag: #ACC24 3.

Heart Failure 111

Heart Failure Atherosclerosis Cardiovascular Imaging Non-Invasive Cardiology 111

DAIC

MAY 18, 2024

Researchers presented these findings “Late Breaking Clinical Trials and Science – CIEDs: Early Cardiac Resynchronization Therapy for Patients with Moderately Reduced Ejection Fraction and Left Bundle Branch Block” this morning during the May 16-19 meeting of the Heart Rhythm Society , HRS 2024 , being held in Boston, MA. Approximately 6.7

Heart Failure 52

Heart Failure Heart Rhythm Research Pacemaker 52

CardiacWire

NOVEMBER 15, 2023

The AHA 2023 Scientific Sessions are officially complete. Prevention & Detection – Boosted by GLP-1 obesity buzz and the fact that cardiovascular outcome trends have been headed in the wrong direction, AHA 2023 placed a greater focus on prevention. heart failure).

Blood Pressure 52

Blood Pressure AFIB Obesity Heart Failure 52

European Journal of Heart Failure

DECEMBER 11, 2024

Abstract Worldwide, valvular heart disease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock.

Cardiogenic Shock 68

Cardiogenic Shock Heart Disease Heart Failure Bicuspid/Mitral 68

All About Cardiovascular System and Disorders

OCTOBER 16, 2023

Current Role of Digoxin in Heart Failure as Per Guidelines and DIGIT-HF trial of Digitoxin Use of digoxin in heart failure has come down markedly over the past decades due to concerns of toxicity and availability of more effective medications. Eur Heart J. Erratum in: Eur Heart J. Eur J Heart Fail.

Heart Failure 52

Heart Failure Atrial Fibrillation Document Hospital 52

Journal of Cardiovascular Electrophysiology

APRIL 10, 2025

ABSTRACT Background Despite leadless pacemakers (LPMs) showing promise, real-world data comparing them to transvenous pacemakers (TV-VVI) are insufficient and often contradictory, especially in patients without major comorbidities like heart failure. Objectives Comparing LPMs with TV-VVIs in real-world patients without HF.

Pacemaker 40

Pacemaker Heart Failure Atrial Fibrillation Bradycardia 40

European Journal of Heart Failure

NOVEMBER 19, 2024

Knowledge and application of European Society of Cardiology/Heart Failure Association (ESC/HFA) guidelines in the management of advanced heart failure (HF). Methods and results From June to October 2023, an online survey was disseminated through the ESC mailing list, targeting cardiologists across Europe.

Heart Failure 40

Heart Failure Transplant Heart Transplant Education 40

DAIC

JANUARY 15, 2024

Cardiac amyloidosis is a heterogeneous disease that results from the accumulation of abnormal proteins within the heart, impairing its ability to pump blood. Over time, the build-up of these proteins causes the heart muscle to stiffen, eventually leading to heart failure, which can have dire outcomes if not found early.

Ultrasound 119

Ultrasound Coronary Artery Disease Innovation Heart Failure 119

Circulation: Cardiovascular Quality & Outcomes

NOVEMBER 1, 2023

Circulation: Cardiovascular Quality and Outcomes, Volume 16, Issue 11 , Page e000123, November 1, 2023. Enhancing access to care using telehealth is a priority for improving outcomes among older adults with heart failure, increasing quality of care, and decreasing costs.

Heart Failure 40

Heart Failure COVID-19 Circulation Outcomes 40

The American Journal of Cardiology

DECEMBER 30, 2023

Publication date: Available online 29 December 2023 Source: The American Journal of Cardiology Author(s): Lorenzo Braghieri, Arwa Younis, Chadi Tabaja, Pasquale Santangeli, Tyler Taigen, Walid I. Saliba, Oussama M. Wazni, Ayman A.

Quality of Life 52

Quality of Life Atrial Fibrillation Heart Failure Ablation 52

DAIC

DECEMBER 29, 2023

Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF.

Atrial Fibrillation 115

Atrial Fibrillation Ablation Atrial Flutter Blood Clot 115

European Journal of Heart Failure

FEBRUARY 25, 2025

Differences in heart failure with preserved ejection fraction (HFpEF) management across medical specialties. Methods and results An independent web-based survey was distributed globally between May and July 2023. A large majority of HFpEF patients are cared by non-cardiologists.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Outcomes Research 40

Journal of the American Heart Association

JANUARY 16, 2024

Journal of the American Heart Association, Volume 13, Issue 2 , January 16, 2024. BackgroundHeart failure disproportionately affects individuals residing in rural areas, leading to worse health outcomes. Digital health interventions have been proposed as a promising approach for improving heart failure management.

Heart Failure 45

Heart Failure Biomarkers Article Technology 45

Frontiers in Cardiovascular Medicine

MARCH 10, 2024

There are conflicting sources regarding the relationship between hyperglycemia and outcomes in STEMI patients. We aimed to compile evidence to assess the association between hyperglycemia and adverse outcomes. Results The 66 included articles spanned the years 2005–2023. 2.17), heart failure (pooled RR 1.56, 95% CI: 1.37–1.77),

Myocardial Infarction 59

Myocardial Infarction Cardiogenic Shock Article STEMI 59

European Journal of Heart Failure

OCTOBER 25, 2024

We used heart failure (HF) guidelines as a paradigm to examine this concern, by conducting a survey to understand clinicians' ability to implement HF guidelines and their perceptions of the current HF guideline applicability in low- and middle-income countries (LMIC).

Heart Failure 40

Heart Failure Outcomes Research Article 40

Journal of Cardiovascular Pharmacology

OCTOBER 9, 2023

Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent one of the most important pharmacological innovations in the field of Cardiology of the last decades, having shown significant outcome improvement in all the heart failure (HF) spectrum. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Heart Failure 40

Heart Failure Pharmacology Innovation Outcomes 40

Circulation

NOVEMBER 11, 2024

Introduction:Guidelines have recognized the critical role of self-care in heart failure (HF), but people with HF do not adequately practice self-care. Outcomes of interest were measured at baseline, 6 weeks (T1), and 3 months (T2) after enrollment. Control group participants only received the usual care.

Nursing 40

Nursing Heart Failure Quality of Life Outcomes 40

Circulation: Heart Failure

OCTOBER 27, 2023

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010524, November 1, 2023. The role of obesity in RV dysfunction and adverse outcomes is unclear.METHODS:We examined patients undergoing right heart catheterization between 2005 and 2016 in a hospital-based cohort. Over median of 7.3

Obesity 40

Obesity Outcomes Heart Failure Pulmonary 40

DAIC

FEBRUARY 2, 2024

Successful six-month results from the randomized controlled pivotal trial, TRISCEND II, were presented at TCT 2023 and reported favorable safety and effectiveness outcomes, demonstrating superiority to OMT alone and meeting all primary endpoints.

Tricuspid 100

Tricuspid Quality of Life Bicuspid/Mitral Innovation 100

Circulation: Cardiovascular Interventions

NOVEMBER 9, 2023

Background:There are limited data about changes in cardiac function (cardiac reverse remodeling) and heart failure indices after transcatheter tricuspid valve-in-valve replacement (TT-VIVR).

Congenital Heart Disease 40

Congenital Heart Disease Tricuspid Heart Failure Congenital 40

Journal of the American Heart Association

NOVEMBER 29, 2023

Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundLittle is known about outcomes following heart failure (HF) hospitalization among adults with congenital heart disease (CHD) in the United States.

Congenital Heart Disease 40

Congenital Heart Disease Congenital Heart Failure Heart Disease 40

Journal of Cardiovascular Pharmacology

MARCH 24, 2024

Abstract: To synthesize the available evidence regarding differences in the long-term safety and efficacy of intermittent, repeated, or continuous palliative inotropic therapy among patients with advanced heart failure (HF).

Heart Failure 40

Heart Failure Outcomes Article 40

Journal of Cardiovascular Pharmacology

SEPTEMBER 7, 2023

This study aimed to compare the cost-effectiveness of the new quadruple therapy regimen of adding sodium-glucose–linked transporter 2 (SGLT2) inhibitors, with standard treatment for patients with heart failure (HF) in China. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Heart Failure 40

Heart Failure Outcomes Article 40

Journal of Cardiovascular Electrophysiology

FEBRUARY 13, 2024

Abstract Introduction Heart failure (HF) and atrial fibrillation (AF) frequently co-exist. A systematic search of PubMed, EMBASE, and Cochrane Library databases until February 28, 2023. Aggregate data comparing the risk profile of AF between these three HF categories are lacking.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Hospital 40

Stroke Journal

JANUARY 30, 2025

Primary outcome was ischemic stroke, while secondary outcomes were all-cause mortality, heart failure, cardiogenic shock, MACE (composite of all-cause mortality, heart failure, and ischemic stroke), and acute kidney injury (AKI).Result:After 0.89), P<0.001), and after 1 year (RR, 0.91 (95% CI: 0.86-0.96),

Cardiogenic Shock 40

Cardiogenic Shock Stroke Strokes Outcomes 40

Circulation: Cardiovascular Interventions

MARCH 17, 2025

In multivariable analyses, the risk of 1-year heart failure readmission for ventricular functional MR was not higher than for DMR (P=0.10642), while patients with chronic ischemic MR and atrial MR had a 19% higher risk of 1-year heart failure readmission compared with DMR (P=0.00493) even if they had a successful procedure.

Bicuspid/Mitral 40

Bicuspid/Mitral Outcomes Heart Failure Cardiovascular Interventions 40

Stroke Journal

JANUARY 30, 2025

Primary outcome was risk of ischemic stroke while secondary outcomes were all-cause mortality (ACM), heart failure, acute myocardial infarction (AMI), major adverse cardiovascular events (MACE), atrial fibrillation (AF), and ventricular tachycardia (VT).Result:After 0.46), P<0.01), AMI after 1 year (RR, 0.55(95%CI:

Outcomes 40

Outcomes Atrial Fibrillation Heart Failure Tachycardia 40

Journal of the American Heart Association

NOVEMBER 28, 2023

Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundWhether statin use can reduce the risk of heart failure (HF) remains controversial. The primary outcome was incident HF. The median age of the cohort was 74.7 years, years, and 47.3% were women.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Outcomes 40

Circulation

JANUARY 24, 2024

METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.

Heart Disease 81

Heart Disease Peripheral Arterial Disease Stroke Strokes 81

DAIC

DECEMBER 22, 2023

milla1cf Fri, 12/22/2023 - 08:21 December 22, 2023 — HeartBeam, Inc., With their expertise and acumen, I am confident both will make an immediate impact to harness the power of AI within our data-rich VECG technology to ensure we deliver the most impactful technology with the goal of improving patient outcomes,” added Dr. Vajdic.

Technology 105

Technology Electrocardiogram Heart Rhythm Biomarkers 105

DAIC

JUNE 27, 2024

By leveraging Anumana's ECG-AI algorithms, developed and validated in collaboration with Mayo Clinic, this initiative aims to enhance InfoBionic.Ai’s MoMe ARC Platform’s ability to detect and intervene in cardiac diseases earlier in the remote patient monitoring setting, with the potential to improve patient outcomes.

Technology 105

Technology Heart Rhythm Innovation Heart Failure 105

DAIC

FEBRUARY 29, 2024

This year’s theme, “Advancing Cardiovascular Care for All” brings the latest practice-changing breakthroughs, along with top experts debating and discussing outcomes of highly-anticipated clinical trials. 24 from April 6 - 8, 2024 in Atlanta, GA at the Georgia World Congress Center. The Guidelines Sessions at ACC.24

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

International Journal of Cardiovascular Sciences

JULY 11, 2024

The Award will correspond to articles published in 2023. The Award will be given to the national authors of the best Original Article published in the journals ABC Cardiol, IJCS, ABC Imagem, and ABC HF in 2023. for enrollment in courses at the Heart University. Awards granted: a) Plaque for each awarded article.

Article 52

Article Plaque Heart Failure Cardiomyopathy 52